Is FMS a Buy or a Sell? The Bull and Bear Case (2026)

That depends on which case you find more convincing, and both are on this page. The bull case rests on The FME25+ cost program, with revenue (ttm) at ~$19.4B (reported in euros). The bear case rests on the long-term structural worry is that GLP-1 drugs and SGLT2 inhibitors slow the progression of chronic kidney disease enough to shrink the future dialysis population, a thesis the company disputes on the grounds that better survival can also increase treatment years. Analysts covering it are spread from $17.37 to $38.22, which is itself a signal that this is genuinely contested. If you believe the thesis, the real questions become sizing and overlap rather than timing. Walnut is not an investment adviser and this is not a recommendation.

Nobody can answer that for you, and the honest version of the question is narrower: has anything changed in the reason you bought it? The bear case on this page is the place to check. The long-term structural worry is that GLP-1 drugs and SGLT2 inhibitors slow the progression of chronic kidney disease enough to shrink the future dialysis population, a thesis the company disputes on the grounds that better survival can also increase treatment years. If that risk is what you were worried about and it is now playing out, that is a real signal. If the price simply fell while the thesis held, that is a different situation entirely. The most pessimistic published target is $17.37, -26.9% from the $23.77 price, which is one analyst's downside case rather than a floor. Walnut is not an investment adviser.

The FME25+ cost program. The transformation program is the main reason flat revenue is producing double-digit income growth, contributing about EUR 67 million of sustainable savings in the second quarter of 2026 alone. The most optimistic analyst target on FMS is $38.22, +60.8% from the $23.77 price. That figure is only reachable if this thesis works close to its best case.

The long-term structural worry is that GLP-1 drugs and SGLT2 inhibitors slow the progression of chronic kidney disease enough to shrink the future dialysis population, a thesis the company disputes on the grounds that better survival can also increase treatment years. Legal exposure is real and ongoing: the Department of Justice has intervened in a False Claims Act case alleging medically unnecessary vascular procedures at a Fresenius subsidiary, and the 2024 recall of 2008 series hemodialysis machines over compounds leaching from silicone tubing has drawn product-liability attention. Because the company reports in euros while earning most of its revenue in dollars, headline growth can diverge sharply from constant-currency growth, which is why the two figures differ by several points in most quarters. US clinic labour costs and nurse availability remain a persistent margin pressure, and leverage is meaningful for a business with this little top-line growth. As a German issuer, dividends are subject to German withholding tax before they reach a US ADS holder, and the company files as a foreign private issuer rather than on the domestic quarterly schedule. The most pessimistic published target is $17.37, -26.9% from the current price, which is roughly what the stock is worth if these risks bite rather than the drivers.

The world's largest dialysis company: a global clinic network plus the machines, dialyzers and consumables that clinics run on.

Decide that in advance, because it is far harder to think clearly once a position is moving against you. The concrete tripwires here: the driver behind the bull case (The FME25+ cost program) stalling in the reported numbers rather than in the narrative, the risk above (the long-term structural worry is that GLP-1 drugs and SGLT2 inhibitors slow the progression of chronic kidney disease enough to shrink the future dialysis population, a thesis the company disputes on the grounds that better survival can also increase treatment years) turning from a possibility into a reported fact, or the position growing large enough that a bad outcome would matter to your whole portfolio regardless of who is right.

It provides dialysis to people whose kidneys have failed, running the largest network of outpatient dialysis clinics in the world, and it manufactures the machines and consumables used to deliver that treatment. The two activities are reported as Care Delivery and Care Enablement. A typical hemodialysis patient attends three sessions a week, so revenue is recurring and tied to patient counts rather than to discretionary spending.

No, it is a claim on them. FMS is an American Depositary Share trading on the NYSE, and each ADS represents one half of one ordinary share listed in Frankfurt. That ratio has changed historically, moving to two ADS per ordinary share in December 2012, which is why old per-share figures do not line up with the ADS price. Dividends and financial statements are denominated in euros and converted for ADS holders.

Yes. The company's own investor materials list both the Frankfurt Stock Exchange for the ordinary shares and the NYSE for the ADS under the ticker FMS. Confusion on this point usually traces back to the 2023 change of legal form from a KGaA partnership structure to an AG, which was a corporate reorganisation rather than a delisting.